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Patients with a solid organ transplant have in-
creased in numbers and in individual survival in
Switzerland over the last decades. As a conse-
quence of long-term immunosuppression, skin
cancer in solid organ recipients (SOTRs) has been
recognized as an important problem. Screening
and education of potential SOTRs about preven-
tion of sun damage and early recognition of skin
cancer are important before transplantation.
Once transplanted, SOTRs should be seen by a
dermatologist yearly for repeat education as well
as early diagnosis, prevention and treatment of
skin cancer. Squamous cell carcinoma of the skin
(SCC) is the most frequent cancer in the setting
of long-term immunosuppression. Sun protection
by behaviour, clothing and daily sun screen appli-
cation is the most effective prevention. Cumula-
tive sun damage results in field cancerisation with
numerous in-situ SCC such as actinic keratosis
and Bowen’s disease which should be treated
proactively. Invasive SCC is cured by complete
surgical excision. Early removal is the best pre-
caution against potential metastases of SCC. Re-
duction of immunosuppression and switch to
mTOR inhibitors and potentially, mycopheno-
late, may reduce the incidence of further SCC.
Chemoprevention with the retinoid acitretin re-
duces the recurrence rate of SCC. The dermato-
logical follow-up of SOTRs should be integrated
into the comprehensive post-transplant care.
Key words: organ transplant; squamous cell carci-
noma of the skin; prevention; sun protection; immuno-
suppression; chemoprevention
Summary
Over the last three decades, improved surgi-
cal techniques and advances in immunosuppres-
sive medication have allowed more and more pa-
tients to benefit from solid organ transplantation.
Worldwide the number of solid organ transplan-
tations performed and graft survival have in-
creased impressively. Graft rejection is suppressed
by combined immunosuppression, which in turn
increases rates of infection and cancer as adverse
events. Cutaneous infections (e.g., human papil-
loma virus (HPV)) and neoplasms (e.g., non
melanoma skin cancer (NMSC) with squamous
cell carcinoma of the skin (SCC) in particular) af-
fect the majority of solid organ transplant recipi-
ents (SOTR) during the course of long-term im-
munosuppression [1].
The increased numbers of transplantations
associated with the improved patient and graft
survival greatly increase the numbers of SOTR in
need of dermatological care. In an attempt to en-
hance the awareness among dermatologists and
other physicians regarding the importance of
careful dermatological monitoring of SOTR for
early diagnosis and prompt treatment, several col-
laborative groups of dermatologists have recently
emerged: The US-led International Transplant –
Skin Cancer Collaborative (ITSCC), the Euro-
pean Skin Care in Organ Transplant Recipients
Europe (SCOPE) Network and, in Switzerland,
the Swiss Society for Dermatology and Venerol-
ogy (SGDV) working group for organ transplan-
tation.
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Joint American and European guidelines for
the prevention and treatment of skin cancers in
SOTR have recently been published [2]. They
are, however, somewhat general in nature due to
the lack of large scale long-term studies address-
ing the care of SCC in SOTR. In order to assist
Swiss physicians in the management of SOTR,
the SGDV working group for organ transplanta-
tion has, in collaboration with the Swiss Society
of Nephrology and the Swiss Society of Trans-
plantation, put together the present clinical
guidelines for the management of skin cancer in
SOTR. We based these recommendations on the
best available evidence and on collective clinical
experience. Our recommendations are graded in
accordance with the Oxford Centre for Evidence-
Based Medicine [3].
Pretransplantation screening
A dermatological consultation is recom-
mended before transplantation to examine and/or
to treat current skin disease, in particular skin can-
cer, to assess the risk of skin tumours following
transplantation and to instruct the patient in pre-
vention and early recognition of skin disease (rec-
ommendation level D) (table 1) [4]. History-tak-
ing should cover extent of lifetime UV exposure,
frequency of sunburns, patient and family history
of skin cancer as well as past and present HPV-as-
sociated verrucae, actinic keratosis (AK), Bowen’s
disease (BD) and invasive skin cancer, in particular
SCC, basal cell carcinoma (BCC), melanoma, Ka-
posi’s sarcoma (KS) and Merkel cell carcinoma
(MCC). The history should also include previous
long-term immunosuppression such as the use of
azathioprine or calcineurin inhibitors for vasculi-
tis, glomerulonephritis or a previous solid organ
transplant. Other factors causing immunosup-
pression such as HIV status should be noted. A
positive history for SCC and BCC is associated
with increased risk for these tumours following
transplantation (recommendation D). Risk factors
for NMSC in SOTR are given in table 1. A total
body skin examination covering the oral and
anogenital region should be performed. Coun-
selling should explain the importance of UV in
skin carcinogenesis, teach sun avoidance by be-
haviour, clothing and daily sun screen application.
Tanning bed use should be discouraged. Early
recognition of skin cancer should be taught. Pho-
totherapy should be avoided in potential organ
transplant recipients (e.g., nephrogenic pruritus)
to limit further UV damage and skin carcinogene-
sis (recommendation D).
Warts, AK, and BD should be treated before
transplantation. AK should be understood as a
symptom of photodamaged skin with field can-
cerisation and prompt a higher frequency of der-
matological consultations. Invasive skin cancer
should be removed surgically. High-risk squa-
mous cell carcinoma should be discussed with the
transplant physician and may require an observa-
tion period before transplantation.Metastatic skin
cancer is generally an exclusion criterion for
transplantation. A history of melanoma should be
carefully evaluated, in particular if the primary
melanoma measured >1 mm Breslow tumour
thickness and/or diagnosis was made less than
5 years priorly (recommendation D) [5, 6]. Partic-
ular care is mandated in the evaluation and man-
agement of candidates for a second or subsequent
solid organ transplant.
History including skin cancer Light skin type (Fitzpatrick I/II)
risk factors
High UV lifetime exposure with actinic damage
Personal history of AK, BD, SCC, BCC, other skin cancer
Family history for skin cancer
Previous exposition to immunosuppressive drugs
(type and length)
Examination Total body skin examination including oral
and genitoanal region
Treatment Treat present AK, BD, verrucae
Remove invasive skin cancer
Education Sun avoidance by behaviour, clothing,
daily sun screen application
Avoid in-door tanning beds
Self-skin examination monthly, dermatological
examination yearly
Present to dermatologist for growth >4 weeks,
wound non-healing >4 weeks
Dermatological recommendation Avoid phototherapy
to transplant physician
Discuss patient eligibility for transplantation in case
of skin cancer
Initiate retinoid chemoprophylaxis in case of skin cancer
Consider early switch to mTOR inhibitors in case
of skin cancer
Table 1
Pre-transplantation screening recommendations.
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SCC is the most common cancer in the post-
transplant setting [7]. After immunosuppression,
UV is the main factor in cutaneous carcinogenesis
[8]. Immediate post transplant advice is generally
not associatedwith sun-protectionbehaviour, such
as use of sun screen, probably because of stress in
the peritransplant period [9]. Long-term sun pro-
tection behaviour in SOTR needs to be improved
[10]. Therefore, all SOTR should receive educa-
tion about their increased risk of skin cancer, sun
protection and self-skin examination before trans-
plantation and, thereafter, on at least a yearly basis
by a dermatologist (recommendation D).
Education shouldcover theclinical appearance
of common benign, premalignant and malignant
skin lesions. UV protection is based on the three
pillars of avoidance, clothing and sun screen.
Avoidance of sun exposure, particularly between
11am and 3pm, should be recommended. Patients
shouldwear a hatwith awide brim,sunglasses, long
sleeves and trousers whenever possible.The regu-
lar use of high sunprotection factor sunscreens sig-
nificantly reduces the frequency of precancerous
and cancerous skin lesions [11]. Sunscreens with
UVA protection (e.g., Australian norm) and a high
sun protection factor for UVB (e.g., 50+) are thus
recommended for the sunexposed skin of the face,
ears, neck and back of the hands every day, rain or
shine.Tanning bed use is also to be discouraged in
the post-transplant period (recommendation D).
Patients should be encouraged to perform self
skin examination monthly looking for skin cancer
and precursors. In particular they should look for
any new or changing growths including pink
patches or spots, scaly growths, bleeding spots, or
changing moles. In addition, for high risk patients
(i.e., history of high risk squamous cell carcinoma,
melanoma or metastatic disease) a self examina-
tion of the lymph nodes every month is recom-
mended [8]. A growth occurring for >4 weeks or a
wound without healing >4 weeks merit dermato-
logical evaluation (recommendation D).
Patient education addressing sun protection
and self-skin examination should be repeated at
the recommended yearly dermatological exami-
nation. Written information should be provided
to reinforce the oral message delivered by the
dermatologist (recommendation D) [12]. Ade-
quate information material can be provided by
the authors of the current guidelines on request
(http://www.derma.ch/derma/resources/Mem-
bers_AG_OTR_081112.pdf).
Patient education: Sun protection and self-skin examination
Standard management post transplantation
Organ transplant recipients (aswell asotherpa-
tients on long-term immunosuppression) should
be seen by a dermatologist on a yearly basis [4].The
consultation should cover history of new skin le-
sions, sun protection knowledge andbehaviour and
self-skin examination habits. Written information
material on this educational content should be pro-
vided.A full skin examination should be performed
with inspection of the palms and soles, oral cavity,
genitalia and scalp and – for patients with a history
of skin cancer – palpation of the lymph nodes.
Lymph node palpation should include the parotid
gland, a frequent location formetastatic SCC orig-
inating in the facial region (recommendation D).
Potentially due to reduced inflammatory peri-
tumoral infiltrate due to the immunosuppressive
regimen [13], invasive SCC may appear clinically
less conspicuous than in the general population and
is therefore frequently underestimated. Invasive
SCC and lentigo maligna may progress rapidly in
SOTR [14]. The patient should be advised to re-
port immediately if tumours arise, and the physi-
cianmust expect SCC andBCC alsomore often on
less common sites like trunk, lower extremities and
ears [15], as well as doubling of size within a few
weeks [1]. Many other skin diseases such as infec-
tions or drug reactionsmanifest in a clinically atyp-
ical presentation in SOTR [16, 17]. Biopsy should
thus be liberally performed to validate the clinical
diagnosis,direct appropriate therapyand to remove
skin cancer at an early stage. Viral warts can be re-
calcitrant andmay need to be treated more aggres-
sively [18]. Minor injuries like cut wounds and fis-
sures can lead to unusual infections and should not
come in direct contact to food, plants, animals or
earth (recommendation D).
In newly transplanted or younger recipients,
the focus of the yearly consultation should be on
education for prevention. In patients with an-
tecedents of skin cancer, dermatological consulta-
tions should occur more frequently [8] with a focus
on early recognition of skin cancer and treatment
of field cancerisation. Unpublished data suggest
cost-savings in the dermatological cost of care if an
occurrence of invasive SCC can be avoided by pre-
vention and early intervention in SOTRs (Rüegg et
al. in preparation). Currently, there are no pub-
lished data to assess the cost-effectiveness of the
recommended consultation intervals.Table 2 sum-
marises our recommendations for dermatological
consultation (recommendation D).
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a) In-situ SCC (actinic keratosis
and Bowen’s disease)
Early recognition and early therapy of these
lesions is recommended to prevent the develop-
ment of invasive tumours. Typical AK lesions
characterised by hyperkeratosis and macular ery-
thema may be treated without histological confir-
mation. However, the threshold for biopsy should
be low and any questionable, indurated, progres-
sive or refractory lesion should be biopsied (rec-
ommendation D).
Treatment modalities recommended are sum-
marised in table 3. Currently, data clearly distin-
guishing one of these modalities as best are lack-
ing. All treatment choices show clinical efficacy.
Generally, however, longer treatment periods,
more frequent applications and occlusive dress-
ings may be required for success compared to the
general population. Because of concerns about
additional DNA damage and reduced lag time
until radiation-induced cancer induction, radio-
therapy should not be performed for in-situ skin
cancer in SOTR and avoided if possible in inva-
sive SCC.
Field cancerisation refers to a concept of
large areas of sun-damaged skin giving rise to in-
situ and invasive skin cancer repeatedly [19–21].
Early treatment of field cancerisation may slow
subsequent tumour development. Frequently
used modalities for the treatment of field canceri-
sation are 5-FU topically, imiquimod, and photo-
dynamic therapy (cf. table 3).
b) Invasive SCC
Excision is the therapy recommended for in-
vasive SCC. This also extends to keratoacan-
thoma, which histologically can not be clearly dis-
tinguished from highly differentiated SCC. Kera-
toacanthoma in SOTR should be considered as
SCC and therefore treated as such by complete
excision. Complete surgical removal at an early
stage is the best prevention of later metastasis, a
significant problem in SOTR. Early biopsy in sus-
picious lesions is strongly recommended (recom-
mendation D). Standard surgery with margin
control should respect margins of 4 to 6 mm be-
yond any surrounding erythema [65]. Mohs mi-
crographic surgery is warranted in anatomic sites
where tissue conservation is desired [55, 64].
Extensive local disease, spread to lymph nodes or
to distant organs will require individualised and
collaborative treatment. Once SCC has occurred,
SOTR should be seen at closer intervals, as indi-
cated in table 2.Table 3 lists recommendations for
SCC management.
c) Basal cell carcinoma
Tr
eatment of basal cell carcinoma in SOTR
should be performed according to recommenda-
tions for the general population, as recently re-
viewed elsewhere [22]. Because of concerns about
additional DNA damage and reduced lag time
until radiation-induced cancer induction, radio-
therapy is not recommended for basal cell carci-
noma in SOTR (recommendation D).
d) Melanoma
The incidence of melanoma in SOTR is sub-
ject to debate. Compared to the general popula-
tion, some authors deny any increase [23] whereas
others report an up to 8-fold increase [24]. A re-
cent study [25] found a similar outcome of
melanoma in SOTR as compared to prognosti-
cally matched non-immunosuppressed patients. A
larger case series of melanoma in SOTR came to
a similar conclusion (for melanoma <2 mm Bres-
Situation Frequency Typical contents
Pre-transplant Once History
Education
full skin examination
recommendation to
transplant
physician
Post-transplant Yearly Education
full skin examination
In-situ SCC (actinic Every 6 months Education
keratosis, Bowen’s full skin examination
disease) Topical treatment of
field cancerisation
Early cutaneous Every 4–6 months Education
carcinogenesis full skin examination
(1 to 4 NMSC/year) Topical treatment of
field cancerisation
Surgical removal of
invasive SCC
Consider systemic
retinoids
Notify transplant
physician
Moderate cutaneous Every 2–4 months Education
carcinogenesis full skin examination
(5–10 NMSC/year) Topical treatment of
field cancerisation
Surgical removal of
invasive SCC
Initiate systemic
retinoids
Contact transplant
physician
Recommend reduced
immunosuppression
Consider switch to
mTOR inhibitors
Severe cutaneous Every 1–3 months Education
carcinogenesis full skin examination
(>10 NMSC/year) Topical treatment of
field cancerisation
Surgical removal of
invasive SCC
Initiate systemic
retinoids
Contact transplant
physician
Recommend reduced
immunosuppression
Consider switch to
mTOR inhibitors
Table 2
Recommended der-
matological consulta-
tions in SOTR.
In all situations:
Exchange informa-
tion and discuss
management with
transplant team and
primary physician in
charge of the trans-
plant recipient.
Management of skin cancer
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low thickness), but it found that the outcome for
melanoma >2 mm Breslow is worse in SOTR
than in the general population [26]. Currently,
limited by the relatively small numbers reported,
we recommend that melanoma in SOTR should
be treated according to generally applicable
guidelines (recommendation C) [27, 28]. The
benefit of reducing or switching immunosuppres-
sion in metastatic melanoma remains unclear and
should be weighed on an individual basis [29].
e) Kaposi sarcoma
The iatrogenic variant of Kaposi sarcoma
(KS) is 400- to 500-fold increased in SOTR [30]
and occurs in 0.4% of US and European SOTR
[31–33], and in up to 5.3% of SOTR in Saudi
Arabia [34]. KS prevalence after organ transplan-
tation varies greatly depending on the prevalence
of HHV8 infection in the general population.
Most cases of post-transplant KS develop as a re-
sult of viral reactivation [35]. Ethnic background
should thus be considered in the differential diag-
nosis of KS.Although HHV8 viral load in periph-
eral blood mononuclear cells of KS individuals
correlates with tumour burden, due to low inter-
val variations this test cannot be used in clinical
Situation Action Comment
Treat in-situ SCC (actinic Cryotherapy [51]
keratosis, Bowen’s disease)
and field cancerisation
Topical 5-fluorouracil [52]
Topical imiquimod [53]
Topical photodynamic therapy [54]
Curettage [55]
Electrodesiccation [55]
Avoid radiotherapy Additional DNA damage, subdued inflammatory response
Biopsy to recognise invasive SCC Palpable, refractory, enlarging lesions
Document invasive SCC [2] Lesion history duration, growth rate, previous treatment, associated pain
Site and size of lesion
Histology subtype, differentiation, Breslow thickness, perineural
or perivascular involvement, ulceration
Cutaneous satellite lesions
Status of draining lymph nodes Examine clinically
Full skin examination anogenital and mucosal regions included
Recognize less aggressive Tumour size <0.6 cm mask area of the face*, genitalia, hands, feet; <1.0 cm
SCC cheeks, forehead, neck, scalp; <2.0 cm: trunk, extremities [2, 56]
Slow growth
Lack of ulceration
Well-defined clinical margins
Lack of satellite lesions
Histology in situ, keratoacanthoma type, well-differentiated, limited to
papillary dermis, absence of neurotropism or of perivascular
invasion
Recognize aggressive SCC Multiple SCC [2, 57–61]
at risk for invasive growth,
Tumour size >0.6 cm mask area of the face *, genitalia, hands, feet; >1.0 cm:
recurrence or metastasis
cheeks, forehead, neck, scalp; >2.0 cm: trunk, extremities
Indistinct clinical borders
Rapid growth
Ulceration
Location on the mask areas of the face,
scalp, genitalia, digits and within an
anatomic fusion plane
Occurrence in a scar, in an area of
chronic inflammation or in the field
of prior radiotherapy
Recurrence after previous treatment
Presence of satellite lesion
Histology deep extension of tumour into the subcutaneous fat, perineural
invasion, perivascular or intravascular invasion, poor
differentiation
* mask area comprises central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular and postauricular areas,
temple and ear
Table 3
Recommendations
for the management
of primary SCC
in SOTR.
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practice to monitor KS patients nor to predict the
occurrence of KS in transplant recipients [35].
Because of its variable clinical appearance, diag-
nosis of KS should be sought early by biopsy [36].
In case of KS, the whole skin including the mu-
cosae and in particular the palate should be exam-
ined for the presence of further KS lesions.Multi-
ple lesions indicate a higher likelihood of visceral
involvement [36]. A diagnosis of KS should be
discussed with the multidisciplinary transplant
team to determine the work-up for potential vis-
ceral involvement.
Reduction of immunosuppression generally
leads to resolution of iatrogenic (drug-associated)
KS [37–43]. Recently, maintenance of immuno-
suppression with a switch from calcineurin in-
hibitors to mTOR inhibitors has proven success-
ful in renal transplant recipients with resolution
or stabilisation of KS disease. First-line recom-
mendation is, therefore, notification of the trans-
plant team with the recommendation of a switch
from calcineurin inhibitors to mTOR inhibitors,
if this can be performed based on all the variables
(e.g., presence or not of significant proteinuria)
(recommendation C).This switch in immunosup-
pression to mTOR inhibitors has mostly been
documented in renal transplant recipients and –
lacking published data – may not apply to the
same extent to other solid organ transplant recip-
ients. Second-line recommendation to the trans-
plant physician is a reduction in immunosuppres-
sion (recommendation D). Further treatment
modalities are numerous and have been reviewed
extensively elsewhere [36].
f) Rare types of skin cancers
Merkel cell carcinoma appears to be in-
creased in SOTR. Case reports exist for other
types of rare skin cancer such as atypical fibroxan-
thoma, angiosarcoma, leiomyosarcoma, cuta-
neous T- and B cell lymphomas. However, these
tumours are rare even in SOTR and no special
recommendation is given.
Choice and modification of immunosuppressive regimen
Increased skin cancer in SOTR is mainly a re-
sult of the long-term immunosuppression that is
needed to prevent graft rejection. Reduction of
immunosuppression should thus be considered in
all cases of recurrent or aggressive skin cancer, in
particular SCC. The impact of reduced immuno-
suppression on the course of disease has not been
well studied. Recent studies have therefore tried
to find a consensus for recommended measures in
SOTR affected by skin cancer [29]. The best evi-
dence for reducing immunosuppression in post-
transplant skin cancer exists for KS and can thus
be recommended. A likely benefit for reduced im-
munosuppression exists in SCC and should thus
be carefully evaluated by transplant physicians in
moderate and severe cutaneous carcinogenesis,
especially if more aggressive forms of SCC are
present. For all other forms of skin cancer, reduc-
tion of immunosuppression may not outweigh the
quality of life of maintaining immunosuppression
(i.e., preventing rejection) and, thus, should be
considered individually (recommendation D).
Several drugs within currently used immuno-
suppressive regimens are known to have cancer-
promoting effects besides their immunosuppres-
sive properties. Cyclosporine A (CsA) is known to
increase levels of TGFβ and VEGF which poten-
tially can contribute to cutaneous carcinogenesis.
The class of mTOR inhibitors on the other side
has shown antiproliferative effects in vitro and in
vivo. Several studies have shown that once mTOR
inhibitors were either added to regimens with cal-
cineurin inhibitors or were substituted for cal-
cineurin inhibitors, the rate of cutaneous malig-
nancies decreased considerably [44]. These find-
ings were not part of these studies’ primary hy-
potheses, though, and there are currently multi-
centre trials in France, the Netherlands and Ger-
many underway to validate the observation that
mTOR inhibitors may decrease the incidence of
SCC in SOTR.With results from these confirma-
tory trials pending, our current recommendation
to transplant physicians is to consider a switch
from calcineurin inhibitors to mTOR inhibitors
in SOTR with stable transplant function in either
(a) KS (recommendation C), or (b) moderate to
severe cutaneous carcinogenesis of SCC (recom-
mendation C).
Azathioprine has been shown to render cells
susceptible to direct DNA damage by UVA, thus
breaking a current paradigm that only UVB is ab-
sorbed by DNA with direct resulting damage in
the
form of cyclobutane pyrimidine dimers. Aza-
thioprine may furthermore result in increased
photosensitivity to UVA [45]. These two factors
may explain why azathioprine is repeatedly in-
criminated in increased cutaneous carcinogenesis
[46]. Our current recommendation to transplant
physicians is to consider a switch from azathio-
prine to another antimetabolite such as mycophe-
nolate mofetil in SOTR with stable transplant
function with moderate to severe cutaneous car-
cinogenesis of SCC (recommendation D).
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Systemic chemoprevention
Acitretin is a systemic retinoid that has proven
beneficial in the prevention of SCC both in the
general population and in the high-risk group of
SOTR [47–49]. In the latter, the benefit may
reach a dimension of 85% risk reduction for fur-
ther SCC development. Our current recommen-
dation to dermatologists is to consider the intro-
duction of acitretin in SOTR with stable trans-
plant function for moderate to severe cutaneous
carcinogenesis of SCC, and earlier in selected
cases (e.g., more aggressive forms of SCC, exten-
sive field cancerisation, porokeratosis) (recom-
mendation A). Acitretin is given long-term at a
typical dose of 0.4 mg/kg body weight once daily
p.o. (Neotigason
®
). Patient adherence is improved
with a gradually increasing dosing schedule. We
recommend initiation of acitretin at 10 mg in the
morning every other day. After three weeks,
dosage is increased to 10 mg daily for another 3
weeks. Dosage is then increased to 10 mg and 25
mg on alternating days for another 3 weeks. Even-
tually the typical maintenance dose of 25 mg daily
is reached. Using such a strategy, every patient
will experience one dosing scheme of acitretin as
well tolerable to which he may return should ad-
verse effects develop at a higher dose later on (rec-
ommendation D). The most common, dose-de-
pendent side effects are dryness of lips, mouth and
skin in general and hair loss, but are rapidly re-
versible on dose reduction or cessation of ac-
itretin. Liver transaminases should be monitored
biweekly for the first two months and then quar-
terly for drug-induced hepatopathy. Triglycerides
and cholesterol may increase and should be moni-
tored quarterly. Combination with tetracyclines,
methotrexate or vitamin A derivatives is con-
traindicated. Acitretin is known for its strong ter-
atogenicity. Adequate contraception must be
started before initiation and maintained for two
years beyond a potential end of acitretin therapy.
Orally applied capecitabine, which converts
to 5-fluorouracil systemically, has shown benefit
in the chemoprevention for SOTRS in a small
case series and may present an option in off-label
use in the future [50].
Integrated care
The numbers of SOTR experiencing cuta-
neous adverse events in relation to transplanta-
tion, in particular skin cancer, are increasing. For
optimal care of this frequently polymorbid popu-
lation, a close collaboration between dermatolo-
gists and the transplant team is recommended
both for patient education in prevention and for
early treatment of evolving skin cancer. This
should take place in secondary and tertiary med-
ical centres where specialized organ transplant re-
cipient clinics have been initiated within many
dermatology departments. Here, a standard of
care can be defined and maintained along with
transplant physicians, medical residents can be
trained focused on the special aspects of skin care
in SOTR, and clinical as well as laboratory studies
can be conducted. On the other hand, the increas-
ing number of SOTR implies that all dermatolo-
gists should at some point be involved and edu-
cated in the particular needs of this patient group,
because an increasing amount of care will also
have to be provided in a peripheral setting outside
the transplant centre. Exchange of individual clin-
ical information should thus not only take place
between dermatologists and transplant physicians
within large centres, but also between dermatolo-
gists at centres and those in the periphery. The
main objectives of such an integrated care should
be to recognize and communicate to all transplant
physicians involved the current state of cutaneous
carcinogenesis in a given SOTR. It is crucial that
an occurrence of SCC is not seen as isolated
event, but rather as one in a chain of events that
may influence transplant decisions such as the
choice of immunosuppressive regimen, treat-
ments such as field cancerisation or systemic
chemoprevention (recommendation D) and in
some cases decisions regarding subsequent trans-
plantations.
Prof. Rudolf Wüthrich, Nephrology Division Uni-
versity Hospital Zürich, for careful revision, inspiring
input and constructive collaboration. Dr. Beda Müh-
leisen, Dermatology Department University Hospital
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